Freelancer Ltd

FLN Details
· Expanding penetration via acquisitions: Freelancer Ltd (ASX: FLN) stock delivered an outstanding gain by generating 6.97% on January 11, 2017 at the back of positive market sentiments. The group recently acquired Nubelo and Prolancer freelancing marketplaces, to leverage the growing opportunity coming from the Latin America, Spanish and Portuguese markets. Freelancer.com will now be able to enhance their Buenos Aires office presence. This has become one of the fastest growing regions for the company. FLN could expand their Spanish and Portuguese markets share from less than 0.2% to over 10% in just four years with over 1.8 million users and 502,000 projects posted in these markets.

· Recommendation: Investors seem to be bullish on FLN ahead of their results, and we have been maintaining our positive stance on FLN. We give a “Buy” recommendation on the stock at the current price of – $ 1.15

Sims Metal Management Ltd

SGM Details
· Buyback initiatives:  Sims Metal Management Ltd (ASX: SGM) stock rallied over 5% on January 11, 2017 and witnessed a surge of 34.57% in the last three months (as at January 10, 2017) at the back of gains in materials sector. SGM has undertaken an on-market buy-back of up to 10% of its issued capital of 19,740,692 shares over a 12-month period.

· Recommendation: SGM stock is trading at higher levels and close to its 52-week high price, and we maintain a “Hold” recommendation on the stock at the current price of - $ 13.00

Sirtex Medical Ltd

SRX Details
· Delivering dose sales growth at the upper end of the guidance: Sirtex Medical Ltd (ASX: SRX) rose over 3.7% on January 11, 2017 post a rally of 4.14% in the last five days (as at January 10, 2017). Recently, the group reported that their unaudited worldwide dose sales of SIR-Spheres® Y-90 resin microspheres rose 5.6% for the six months ended December 31, 2016, as compared to their prior corresponding period (pcp). As per the Americas division, the group generated a dose sales growth of 5.5% during the period against the issued guidance range of 4% to 6%. EMEA recorded first half dose sales growth of 4.1% as compared to their 2-3% guidance while APAC generated a growth of 10.2% as compared to their forecasts of 8-10%.

· Recommendation: SRX stock corrected over 50.5% in the last three months as the group forecasts were lower than investors’ estimates. However, SRX was able to deliver the dose sales growth at the upper end of their issued 4-6% dose sales guidance of December 2016. We maintain our “Hold” recommendation at the current price of - $ 15.66

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in:  BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.